Company Profile: Coreline Soft Co., Ltd.
Background
Coreline Soft Co., Ltd., established in 2012 and headquartered in Seoul, South Korea, specializes in the development of artificial intelligence (AI)-based medical imaging software. The company's mission is to enhance diagnostic accuracy and efficiency in the detection and analysis of thoracic diseases, including lung cancer, chronic obstructive pulmonary disease (COPD), and coronary artery disease. Coreline Soft's flagship product, AVIEW, is a comprehensive AI-driven platform that supports early detection and structured analysis of these conditions through advanced imaging techniques. The company has achieved significant industry recognition, notably being the official AI solution provider for Korea's national lung cancer screening program (K-LUCAS) since 2017.
Key Strategic Focus
Coreline Soft's strategic focus centers on the development and deployment of AI-powered imaging solutions for thoracic diseases. The company's core objectives include:
- Product Development: Advancing AI algorithms for the detection and analysis of lung diseases, with plans to expand into interstitial lung disease (ILD), idiopathic pulmonary fibrosis (IPF), and infectious pneumonia, including COVID-19.
- Market Expansion: Extending its global footprint by entering markets in North America, Europe, and Australia, leveraging partnerships with local medical device suppliers and healthcare institutions.
- Regulatory Approvals: Securing necessary certifications and clearances to ensure product compliance with international medical device standards.
The company utilizes advanced AI technologies, including deep learning algorithms, to analyze medical imaging data, thereby improving diagnostic precision and workflow efficiency for healthcare professionals.
Financials and Funding
As of May 2025, Coreline Soft's annual revenue is estimated to be between $10 million and $50 million. In March 2025, the company secured a significant investment of approximately 3.4 billion South Korean Won (approximately $2.3 million) from VUNO Inc., a leading AI healthcare company. Additionally, in April 2024, Coreline Soft completed a reverse merger with Shinhan 7th Special Purpose Acquisition Company, facilitating its listing on the KOSDAQ market. The funds from these investments are intended to support ongoing product development, market expansion, and operational scaling.
Pipeline Development
Coreline Soft's product pipeline includes several key AI-powered solutions:
- AVIEW LCS Plus: An AI-driven chest diagnostic solution capable of simultaneously detecting pulmonary nodules, emphysema, and coronary artery calcification.
- AVIEW Lung Nodule CAD: An AI-based lung nodule detection solution that received FDA 510(k) clearance in March 2023, marking its entry into the U.S. medical device market.
- AVIEW Metric-Lung: A quantitative image biomarker software for COPD using chest CT images.
These products are at various stages of development and deployment, with AVIEW LCS Plus and AVIEW Lung Nodule CAD already in use in multiple international markets.
Technological Platform and Innovation
Coreline Soft's technological platform is centered around its proprietary AVIEW system, which integrates deep learning algorithms for the analysis of medical imaging data. The company employs advanced scientific methodologies, including texture analysis and 3D modeling, to enhance diagnostic capabilities. In 2023, Coreline Soft partnered with Bayer AG to integrate its product into Bayer's AI platform, Calantic Medical Imaging, further expanding its technological reach.
Leadership Team
The leadership team at Coreline Soft comprises:
- Jin-Guk Kim: Chief Executive Officer (CEO) and Board Member since 2012.
- Jae-Yeon Lee: Chief Technology Officer (CTO) and Board Member since 2012.
- Woo-Seok Jung: Director of Finance (CFO) and Board Member since March 2024.
These leaders bring extensive experience in medical imaging, AI technology, and business management to the company.
Competitor Profile and Market Insights
The global medical imaging market is experiencing significant growth, driven by advancements in AI and increasing demand for early disease detection. The market is projected to reach $200 billion by 2027, with diagnostic imaging devices accounting for a substantial share.
Coreline Soft faces competition from other medical AI companies such as VUNO Inc., which invested in Coreline Soft in 2025, and global players like Siemens Healthineers. The competitive landscape is characterized by rapid technological advancements and the need for regulatory approvals.
Strategic Collaborations and Partnerships
Coreline Soft has established several strategic collaborations:
- ParagonCare Limited: In July 2025, Coreline Soft partnered with ParagonCare to support Australia's National Lung Cancer Screening Program with its AI-powered chest CT solution, AVIEW LCS Plus.
- Bayer AG: In April 2025, Coreline Soft integrated its product into Bayer's AI platform, Calantic Medical Imaging, enhancing its technological capabilities.
Operational Insights
Coreline Soft's operational strategy focuses on leveraging its AI technology to improve diagnostic accuracy and efficiency in thoracic imaging. The company has successfully implemented its solutions in various international markets, demonstrating the scalability and adaptability of its products.
Strategic Opportunities and Future Directions
Looking ahead, Coreline Soft aims to:
- Expand Market Presence: Increase its footprint in North America and Europe by leveraging existing partnerships and pursuing new collaborations.
- Diversify Product Portfolio: Develop additional AI-driven solutions for other medical imaging applications, including brain and spine imaging.
- Enhance Regulatory Compliance: Obtain necessary certifications and approvals to enter new markets and broaden product adoption.
Contact Information
- Website: corelinesoft.com
- LinkedIn: Coreline Soft
